Two posters compared health care resource utilization (HCRU) and financial burdens of people living with HIV with a non-HIV population and people with HIV who are heavily treated with those have ...
Since its first approval in 2022, Gilead Sciences’ lenacapavir—a twice-yearly injectable—has come to be a potential game ...
The 15 drugs accounted for $27bn in spending via Medicare Part B and Part D between November 2024 and October 2025.
Opinion: "While the obstacles we face may be significant, Lenacapavir represents a monumental breakthrough in the fight ...
A new HIV prevention drug will be made available at a lower cost in over 100 low-income countries within two years — a move expected to give millions access to the breakthrough treatment and ...
Cutting HIV aid means undercutting US foreign and economic interests − Nigeria shows the human costs
A little over two decades ago, addressing Nigeria’s HIV crisis topped U.S. President George W. Bush’s priorities. Africa’s most populous nation had 3.5 million HIV cases, and the disease threatened to ...
The AIDS Healthcare Foundation, the world’s largest HIV/AIDS nonprofit organization, fled a petition in Tallahassee on ...
To quote Florida Surgeon General Joseph Ladapo, “It’s a really, really serious issue.” Here are the facts: More than 32,000 ...
New guidelines update ART choices, endorse long-acting injectables, refine infant feeding advice, and prioritise shorter TB ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results